Aspen, Adcock Ingram and other South African generic drugmakers stand to benefit from the introduction of a more efficient regulator and retailer Clicks’s expansion plans, BMI Research said in a note released on Wednesday. BMI estimated generic drugs sales in SA totalled R16.2bn in 2016, and expected this to grow to R40bn by 2026, equating to a compound annual growth rate of 9.5%. This growth will partly be thanks to the South African Health Products Regulatory Agency (Sahpra) replacing the Medicines Control Council (MCC) in April — if government meets its deadline. The new regulator’s first task will be to clear the backlog of 2,900 applications awaiting registration by the MCC. "The launch of Sahpra will see generic products being fast-tracked and brought to market much sooner than before, making newer generation molecules available to patients at a fraction of the cost," the report quotes Pharma Dynamics’ CEO Erik Roos saying. But BMI’s report noted that the establishment of Sahp...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now